Helicobacter%20pylori%20infection Management

Management

Follow Up

Patient should be re-tested after a minimum of 4 weeks after treatment

It is advisable to confirm eradication of H pylori with a post-treatment UBT, monoclonal stool test or upper endoscopy with biopsy
- Antisecretory drugs especially PPIs should be discontinued at least 1-2 weeks prior to post-test, while Bismuth compounds and antibiotics should be stopped at least 4 weeks prior to test
Patients with either gastric ulcers or complicated duodenal ulcers should have a repeat endoscopy and biopsy, UBT, or stool antigen test to rule out malignancy
In patients with persistent H pylori infection, a culture and sensitivity may be done before retreatment, except when considering a Bismuth-based quadruple therapy
Serology is not used in determining treatment response

Product Highlight - Salofalk

12 Mar 2021

SALOFALK – Mesalazine 1.5 g PR granules

Long COVID: What we have learned so far

Prof. Ghassan Dbaibo, 27 Apr 2023

The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.

Relationship between tumour response to systemic therapy and overall survival in unresectable hepatocellular carcinoma

Dr Raghav Sundar, 09 Sep 2019

Overall survival (OS) is currently the primary criteria in assessing the efficacy of a cancer treatment. Dr Raghav Sundar, a consultant medical oncologist at the National University Hospital, Singapore, details the crucial role played by tumour response in evaluating treatment efficacy, with a focus on the multiple kinase inhibitor lenvatinib in the treatment of hepatocellular carcinoma (HCC).